The production of Necator americanus larvae for use in experimental human infection.


Journal

Parasites & vectors
ISSN: 1756-3305
Titre abrégé: Parasit Vectors
Pays: England
ID NLM: 101462774

Informations de publication

Date de publication:
08 Jul 2022
Historique:
received: 26 02 2022
accepted: 03 05 2022
entrez: 8 7 2022
pubmed: 9 7 2022
medline: 14 7 2022
Statut: epublish

Résumé

Although there is unprecedented interest in experimental human hookworm infection, details of hookworm manufacture and characterisation have been sparsely reported. In this report, we detail the production and characterisation of Necator americanus larvae for use in a recently published clinical trial. Faeces was obtained from an experimentally infected donor. Faecal hookworm DNA was determined by quantitative PCR. Paired samples were incubated in either sterile water or sterile water mixed with antimicrobials (amphotericin and gentamicin). Coproculture was performed by modified Harada-Mori method. The harvested larvae were then processed in either sterile water or antiseptic solution. Larval yield was then calculated (larvae per gram), larval viability was determined by thermally induced motility assay and microbial burden was determined at the day of harvest, at 48 h and at 7 days. Twenty-eight faecal cultures were performed over 16 months. The faecal hookworm DNA content was variable over this time. There was no association of larval yield with faecal hookworm DNA content. Pre-treatment of faeces with antimicrobials did not influence larval yield. Larval motility was 85.3% (95% CI 79.3-91.3%). Incubation of larvae in antiseptics did not reduce viability at 14 days with a marginal mean of 68.6% (95% CI 59.1-78.1%) washed in water vs. 63.3% (95% CI 53.8 - 72.9%) when incubated in betadine (p = 0.38). Larvae washed in sterile water did not meet microbial bioburden criteria. Incubation in antiseptic resulted in acceptable microbial bioburden at 48 h but not at 7 days. Although the addition of gentamicin did reduce the microbial bio-burden acceptable levels, it was found to significantly lower larval motility at 7 days compared to incubation in sterile water and motility at 7 days 37.8% (95% CI 4.7-70.9%) vs. 67.3% (95% CI 35.2-99.3%, p < 0.001), respectively. Despite standardised culture methodologies and the use of a single donor, larval yield varied considerably between batches and had no association with faecal hookworm DNA. Larval viability decreases over time and the age of larvae at time of use are likely to be important. Microbial bioburden maybe temporarily reduced by incubation in antiseptics and has little effect on viability. Incubation of larvae in gentamicin is effective at reducing microbial bioburden but is deleterious to larval viability.

Sections du résumé

BACKGROUND BACKGROUND
Although there is unprecedented interest in experimental human hookworm infection, details of hookworm manufacture and characterisation have been sparsely reported. In this report, we detail the production and characterisation of Necator americanus larvae for use in a recently published clinical trial.
METHODS METHODS
Faeces was obtained from an experimentally infected donor. Faecal hookworm DNA was determined by quantitative PCR. Paired samples were incubated in either sterile water or sterile water mixed with antimicrobials (amphotericin and gentamicin). Coproculture was performed by modified Harada-Mori method. The harvested larvae were then processed in either sterile water or antiseptic solution. Larval yield was then calculated (larvae per gram), larval viability was determined by thermally induced motility assay and microbial burden was determined at the day of harvest, at 48 h and at 7 days.
RESULTS RESULTS
Twenty-eight faecal cultures were performed over 16 months. The faecal hookworm DNA content was variable over this time. There was no association of larval yield with faecal hookworm DNA content. Pre-treatment of faeces with antimicrobials did not influence larval yield. Larval motility was 85.3% (95% CI 79.3-91.3%). Incubation of larvae in antiseptics did not reduce viability at 14 days with a marginal mean of 68.6% (95% CI 59.1-78.1%) washed in water vs. 63.3% (95% CI 53.8 - 72.9%) when incubated in betadine (p = 0.38). Larvae washed in sterile water did not meet microbial bioburden criteria. Incubation in antiseptic resulted in acceptable microbial bioburden at 48 h but not at 7 days. Although the addition of gentamicin did reduce the microbial bio-burden acceptable levels, it was found to significantly lower larval motility at 7 days compared to incubation in sterile water and motility at 7 days 37.8% (95% CI 4.7-70.9%) vs. 67.3% (95% CI 35.2-99.3%, p < 0.001), respectively.
CONCLUSIONS CONCLUSIONS
Despite standardised culture methodologies and the use of a single donor, larval yield varied considerably between batches and had no association with faecal hookworm DNA. Larval viability decreases over time and the age of larvae at time of use are likely to be important. Microbial bioburden maybe temporarily reduced by incubation in antiseptics and has little effect on viability. Incubation of larvae in gentamicin is effective at reducing microbial bioburden but is deleterious to larval viability.

Identifiants

pubmed: 35804460
doi: 10.1186/s13071-022-05371-y
pii: 10.1186/s13071-022-05371-y
pmc: PMC9264692
doi:

Substances chimiques

Anti-Infective Agents, Local 0
Gentamicins 0
Water 059QF0KO0R

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

242

Informations de copyright

© 2022. The Author(s).

Références

J Allergy Clin Immunol. 2015 Feb;135(2):508-16
pubmed: 25248819
Adv Parasitol. 1978;16:333-42
pubmed: 364958
Lancet Infect Dis. 2021 Dec;21(12):1725-1736
pubmed: 34419209
Gut. 2006 Jan;55(1):136-7
pubmed: 16344586
PLoS One. 2011 Mar 08;6(3):e17366
pubmed: 21408161
Antimicrob Agents Chemother. 2013 Nov;57(11):5423-5
pubmed: 23959311
PLoS Negl Trop Dis. 2021 Jan 22;15(1):e0009032
pubmed: 33481808
Gastroenterology. 2006 Aug;131(2):402-9
pubmed: 16890593
Clin Exp Allergy. 2009 Jul;39(7):1060-8
pubmed: 19400893
Int J Parasitol. 2014 Oct 1;44(11):765-74
pubmed: 24992655
JAMA Neurol. 2020 Sep 1;77(9):1089-1098
pubmed: 32539079
Open Forum Infect Dis. 2018 Apr 19;5(5):ofy083
pubmed: 29780848
Clin Exp Allergy. 2010 Feb;40(2):299-306
pubmed: 20030661
Trans R Soc Trop Med Hyg. 2007 Feb;101(2):140-5
pubmed: 16824566
Clin Transl Gastroenterol. 2020 Dec;11(12):e00274
pubmed: 33512796
PLoS Negl Trop Dis. 2016 Jan 28;10(1):e0004380
pubmed: 26820626
J Infect Dis. 2019 Aug 9;220(6):1044-1048
pubmed: 31077279
Am J Trop Med Hyg. 2004 Nov;71(5):608-16
pubmed: 15569793
J Infect Dis. 2021 Mar 3;223(5):905-913
pubmed: 32645714
PLoS Negl Trop Dis. 2021 Dec 9;15(12):e0009908
pubmed: 34882670
Exp Parasitol. 1987 Apr;63(2):136-42
pubmed: 3569472

Auteurs

Paul R Chapman (PR)

Clinical Tropical Medicine, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia. paul.chapman@health.qld.gov.au.
RBWH Infectious Diseases, Bowen Hills and Herston, Australia. paul.chapman@health.qld.gov.au.

Stacey Llewellyn (S)

Statistics Unit, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.

Helen Jennings (H)

Clinical Tropical Medicine, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.

Luke Becker (L)

Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia.

Paul Giacomin (P)

Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia.

Rodney McDougall (R)

Sullivan Nicolaides Pathology, Bowen Hills and Herston, Australia.

Jennifer Robson (J)

Sullivan Nicolaides Pathology, Bowen Hills and Herston, Australia.

Alex Loukas (A)

Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia.

James McCarthy (J)

Centre for Molecular Therapeutics, Australian Institute of Tropical Health and Medicine, James Cook University, Cairns, QLD, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH